Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Euphorbia Kansui for HIV-1 Latency
NCT04503928Phase 1Unknown
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- HM (Herbal Medicine), TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Euphorbia kansui in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoints: Change in plasma HIV-1 RNA concentration at Day 21, Change in cell-associated HIV-1 RNA at Day 21 and 1 more. Status: unknown.
02
Drugs
Euphorbia kansui
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04503928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503928.